Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome

Figures

• 

  Figure 1.. Overall design of the WILL lOWer dose aspirin be more effective in ACS? (WILLOW ACS) study. ACS, acute coronary syndrome; BD, twice daily; mg, milligrams; OD, once daily; R, point of randomization.

• 

  Figure 2.. Serum TXB2 (a) and bleeding time (b) in ACS patients receiving two regimens of aspirin and ticagrelor in the WILLOW ACS study. Bars represent mean + SD. Dots and lines represent paired values for the individual participants. p values shown were generated by paired t-tests between the groups (see text and tables for further details). BD, twice-daily; OD, once-daily s, seconds; sTXB2, serum thromboxane B2. the groups (see text and tables for further details). Scale on the y-axis in Figure 2(a) is logarithmic. BD, twice-daily; OD, once-daily s, seconds; TXB2, thromboxane B2.

• 

  Figure 3.. Maximum platelet aggregation responses to arachidonic acid, adenosine diphosphate and collagen assessed by light transmittance aggregometry pre- and post-aspirin dose at the end of each treatment period in the WILLOW ACS study. Bars indicate mean + SD. p values were generated using prespecified paired t-tests. AA, arachidonic acid; ADP, adenosine diphosphate; BD, twice-daily; OD, once-daily.

• 

  Figure 4.. Urinary levels of TX metabolite, PGI2 metabolite 8-iso-PGF2α measured at the end of each treatment period. Bars represent mean + SD. Dots and lines represent paired values for the individual participants. p values shown were generated by paired t-tests between the groups. Scale on the y-axis is logarithmic. 8-iso-PGF2α, 8-iso prostaglandin F2α; BD, twice- daily; PGI-M, prostacyclin metabolite; OD, once-daily; TxM, thromboxane metabolite.

• 

  Figure 5.. Conceptual figure summarizing the anticipated profiles of COX-1 inhibition and hemostasis provided by maintenance aspirin doses of 75 mg OD or 20 mg BD in combination with ticagrelor 90 mg BD, during steady-state. Figure for illustrative purposes only, scale on the y-axis is arbitrary. Dashed line represents effects on COX-1 and hemostasis at steady-state trough levels. BD, twice-daily; COX-1, cyclo-oxygenase 1; mg, milligrams; OD, once-daily.